Table 1 Major clinical trials of TCR-T cell therapies for solid tumor patients
Disease | Antigen | HLA | TCR-T cell source | Clinical trial number | Phase | Status |
|---|---|---|---|---|---|---|
Melanoma | MART-1 | HLA-A*02:01 | PB (patient) | NCT00910650 | II | Completed |
| Â | MART-1 | HLA-A*02:01 | PB (patient) | NCT00509288 | II | Completed |
| Â | MAGE-A3 | HLA-DP*04:01/04:02 | PB (patient) | NCT02111850 | I/II | Completed |
| Â | MAGE-C2 | HLA-A*0201 | PB (patient) | NCT04729543 | I/II | Recruiting |
| Â | PRAME | HLA-A*02 | PB (patient) | NCT03686124 | I | Recruiting |
| Â | NY-ESO-1 | HLA-A*0201 | PB (patient) | NCT03638206 | I/II | Recruiting |
| Â | MAGE-A3/12 | HLA-A*02:01 | PB (patient) | NCT01273181 | I/II | Terminated |
| Â | NY-ESO-1 | HLA-A*02:01 | PB (patient) | NCT00670748 | II | Terminated (A more highly selected protocol with ESO TCR opened for pts with melanoma) |
| Â | gp 100 | HLA-A*02:01 | PB (patient) | NCT00509496 | II | Terminated (Low accrual) |
| Â | PRAME | HLA-A*02:01 | PB (patient) | NCT02743611 | I/II | Unknown |
Lung cancer | NY-ESO-1 | HLA-A*02 | PB (patient) | NCT02457650 | I | Unknown |
| Â | NY-ESO-1/LAGE-1a | HLA-A*02:01 HLA-A*02:05 HLA-A*02 | PB (patient) | NCT03709706 | Ia/IIb | Active not recruiting |
Sarcoma | NY-ESO-1 | HLA-A*02 | PB (patient) | NCT01343043 | I | Completed |
| Â | MAGE-A4c1032 | HLA-A*02 | PB (patient) | NCT03132922 | I | Active not recruiting |
Renal cell carcinoma | HERV-E | HLA-A*11:01 | CD8+/CD34+ T cell (patient) | NCT03354390 | I | Recruiting |
| Â | TRAIL | / | PB (patient) | NCT00923390 | I/II | Terminated |
Bladder cancer | MAGE-A10c796 | HLA-A*02:01 HLA-A*02:06 | T cells (patient) | NCT02989064 | I | Completed |
| Â | MAGE-A3 | HLA-A*01 | PB (patient) | NCT02153905 | I/II | Terminated (Slow, insufficient accrual) |
Esophageal cancer | MAGE-A4 | HLA-A*24:02 | Lymphocytes (patient) | UMIN000002395 | I | Completed |
Metastatic cancer | CEA | HLA-A*02:01 | PB (patient) | NCT00923806 | I | Terminated (Study was terminated due to poor accrual) |
Pancreatic cancer | KRAS G12D | HLA-C*08:02 | TIL (patient) | NCT03935893 | II | Recruiting |
Hepatocellular carcinoma | HBV | HLA-A*02:01 HLA-Cw*08:01 | PBMC (patient) | NCT03899415 | I | Recruiting |
| Â | AFPc332 | HLA-A*02 | T cells (patient) | NCT03132792 | I | Recruiting |
HPV+ cancer | HPV-16 E6 | HLA-A*02 | PB (patient) | NCT02280811 | I/II | Completed |
| Â | HPV-16 E7 | HLA-A*02 | PB (patient) | NCT02858310 | I/II | Recruiting |